Adamis Pharmaceuticals Schedules Financial Results Conference Call and Business Update
November 19 2021 - 3:34PM
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a
biopharmaceutical company developing and commercializing specialty
products for allergy, opioid overdose, respiratory and inflammatory
disease, today announced that it will host an investor conference
call on Monday, November 22, 2021 at 2 p.m. Pacific Time to discuss
its financial and operating results for the first nine months of
2021, as well as provide a business update. The Company’s press
release concerning its financial results will be available after 1
p.m. Pacific Time on November 22, 2021 and on its website at
www.adamispharmaceuticals.com, and the company also expects to file
its quarterly reports on Form 10-Q for the quarters ended March 31,
2021, June 30, 2021 and September 30, 2021 on that date.
Event: Adamis Pharmaceuticals Financial Results Conference
CallDate: Monday, November 22, 2021Time: 2 p.m. PT (5 p.m. ET)U.S.
Dial-in (Toll Free): 1-877-423-9813Toll/International Dial-in:
1-201-689-8573Conference ID: 13725311
Dennis J. Carlo, Ph.D., President and CEO of Adamis, will host
the call along with other members of the management team. The call
is open to the public and will provide an update on recent
developments, events that have taken place during the year, and
certain goals for future periods. Forward-looking statements
concerning expectations regarding future company performance may be
made during the conference call.
A live audio webcast of the conference call will also be
available via this link –
https://viavid.webcasts.com/starthere.jsp?ei=1515468&tp_key=857fdc0361,
with a replay available shortly after the live event.
About Adamis Pharmaceuticals
Adamis Pharmaceuticals Corporation is a specialty
biopharmaceutical company primarily focused on developing and
commercializing products in various therapeutic areas, including
allergy, opioid overdose, respiratory and inflammatory disease. The
Company’s SYMJEPI (epinephrine) Injection products are approved by
the FDA for use in the emergency treatment of acute allergic
reactions, including anaphylaxis. The Company’s ZIMHI (naloxone)
Injection product is approved for the treatment of opioid overdose.
Tempol is in development for the treatment of patients with
COVID-19 and a Phase 2/3 clinical trial is underway. For additional
information about Adamis Pharmaceuticals, please visit
www.adamispharmaceuticals.com and follow us on Twitter and
LinkedIn.
Contact:
Adamis Investor Relations Robert UhlManaging DirectorWestwicke
ICR619.228.5886robert.uhl@westwicke.com
Adamis Pharmaceuticals (NASDAQ:ADMP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Adamis Pharmaceuticals (NASDAQ:ADMP)
Historical Stock Chart
From Sep 2023 to Sep 2024